ADMA Biologics Stock Gains On FDA Approval For Plasma Collection Facility

·1 min read
  • The FDA has approved ADMA Biologics Inc's (NASDAQ: ADMA) BioCenters plasma collection facility in Maryville, Tennessee.

  • The plasma collection facility commenced operations and initiated source plasma collection in Q4 of 2020.

  • With today's approval, the facility is now licensed to collect and introduce into interstate commerce human source plasma for further manufacturing in the U.S.

  • ADMA has eight plasma collection facilities, including three FDA-approved facilities. Five of those facilities are now open and collecting plasma, and two additional marketing applications are anticipated over the remainder of 2021.

  • In total, ADMA remains on track to have 10 or more FDA-approved plasma collection facilities by 2024.

  • Price Action: ADMA shares are up 13.4% at $1.69 during the premarket session on the last check Monday.

  • Related content: Benzinga's Full FDA Calendar.

See more from Benzinga

© 2021 Benzinga does not provide investment advice. All rights reserved.